drugset / Trial / NCT07004647
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, dose-escalation, investigator-initiated exploratory clinical trial designed to evaluate the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of MT027 Cell Injection in patients with advanced primary or secondary peritoneal tumors.
Timeline
- Start
- 2025-03-15
- Primary completion
- 2028-10-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT027 | Cell therapy | 1e+07 cells | Intrathecal |
| Subject | MT027 | Cell therapy | 3e+07 cells | Intrathecal |
| Subject | MT027 | Cell therapy | 6e+07 cells | Intrathecal |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |